Neue ESC-Leitlinie zur Herzinsuffizienz – Ivabradin als wichtige Behandlungsoption aufgenommen

• Literatur

• 1 Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHI_fT): a randomised placebo-controlled trial. Lancet 2012; 376: 875-885
• 2 McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 19.05.2012; [Epub ahead of print]
• 3 Fachinformation Procoralan®. 02/2012
• 4 Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHI_fT study. Clin Res Cardiol 11.05.2011; [Epub ahead of print]
• 5 Swedberg K. Effects on Outcomes of heart rate reduction by Ivabradine in patients with congestive heart failure: Is there an influence of beta-blocker dose? Findings from the SHI_fT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) Study. J Am Coll Cardiol 22.02.2012; [Epub ahead of print]
• 6 Komajda M, Böhm M, Borer JS et al. Ivabradine improves clinical outcomes in patients with chronic systolic heart failure taking aldosterone antagonists: findings from SHI_fT trial. Eur J Heart Failure supplements 2012; 11 (Suppl. 01) 121 Heart Failure 2012, abstract #683
• 7 Tardif JC, O'Meara E, Komaida M et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIIFT echocardiography substudy. Eur. Heart J 2011; 32: 2507-2515
• 8 Ekman I, Chassany O, Komajda M et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHI_fT study. Eur. Heart J 2011; 32: 2395-2404